Powered by

TLC and 3SBio Form Exclusive Partnership to Commercialize Two NanoX„¢ Products in Mainland China

Mar 03, 2019 - GlobeNewswire

SOUTH SAN FRANCISCO, Calif., TAIWAN, SHEN YANG, China and HONG KONG, March 04, 2019 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. ("TLC")(Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, and 3SBio Inc. ("3SBio")(HKEX: 1530), a leading Chinese biopharmaceutical company specializing i...